KRAS and pancreatic ductal adenocarcinoma: Cite this article as: Ardalan B, Azqueta J, Sleeman D (2021) Cobimetinib plus gemcitabine: an active combination in KRAS G12R-mutated pancreatic ductal adenocarcinoma patients in previously treated and failed multiple chemotherapies, Journal of Pancreatic Cancer 7:1, 65–70, DOI: 10.1089/pancan.2021.0006.